{"id":15213,"date":"2026-07-03T16:24:37","date_gmt":"2026-07-03T10:54:37","guid":{"rendered":"https:\/\/mdforlives.com\/blog\/?p=15213"},"modified":"2026-07-03T18:31:43","modified_gmt":"2026-07-03T13:01:43","slug":"beyond-triptans-migraine-treatment","status":"publish","type":"post","link":"https:\/\/mdforlives.com\/blog\/beyond-triptans-migraine-treatment\/","title":{"rendered":"Beyond Triptans: New Migraine Treatments Are Helping, But Predictability Still Waits"},"content":{"rendered":"

You do not switch migraine treatment because something new exists.<\/span>\u00a0<\/span><\/p>\n

You switch because something old stopped working. Or because it worked, but the side effects became too much. Or because relief arrived, but not reliably enough to plan your day around it.<\/span>\u00a0<\/span><\/p>\n

That is the real story behind many patient journeys beyond triptans.<\/span>\u00a0<\/span><\/p>\n

Migraine treatment has changed meaningfully in recent years. CGRP-targeted therapies, including monoclonal antibody injections and gepants, have expanded options for prevention and acute treatment. For people who do not respond well to triptans, cannot tolerate them, or worry about frequent acute medication use, these newer options can feel like a long-awaited shift.<\/span>\u00a0<\/span><\/p>\n

But real life is more complicated than availability.<\/span>\u00a0<\/span><\/p>\n

This MDForLives pulse reflects responses from 449 people living with migraine across South Asia, GCC, Western Europe, and the Americas. What emerges is not a simple success story. It is progress, with resistance. Newer migraine treatments are helping many people reduce severity, speed up relief, and feel more confident. But patients are still chasing something harder to measure: days they can trust.<\/span><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n